Showing 7531-7540 of 9718 results for "".
- FDA Approves Deuruxolitinib for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-deuruxolitinib-alopecia-areata/2467563/The U.S. Food and Drug Administration (FDA) has approved deuruxolitinib 8-mg tablets for the treatment of adults with severe alopecia areata, Sun Pharmaceuticals Industries Limited announced in a press release. Deuroxolitinib is available from Sun Pharma under the name LEQSELVI. "
- Analysis: Ruxolitinib 1.5% Cream Linked with Repigmentation in Adolescents with Vitiligohttps://practicaldermatology.com/news/phase-3-trials-reveal-enhanced-repigmentation-adolescents-vitiligo/2467443/A new post-hoc analysis indicates significant repigmentation results from the application of 1.5% ruxolitinib cream in patients with nonsegmental vitiligo. The analysis looked at two double-blind, vehicle-controlled studies (the TRuE-V1 and TRuE-V2 phase 3 clinical trials). Patients were
- Dermaliq Therapeutics Announces Positive Topline Results from Phase 1b/2a Trial of Androgenetic Alopecia Treatmenthttps://practicaldermatology.com/news/dermaliq-therapeutics-announces-positive-topline-results-phase-1b2a-trial-androgenetic-alopecia-treatment/2467422/Dermaliq Therapeutics announced statistically significant topline data from a randomized, blinded, vehicle and comparator-controlled clinical phase 1b/2a trial in men with androgenetic alopecia (male pattern baldness, AGA) for its topical product candidate DLQ01, a prostaglandin F2α analog, based
- Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeuticshttps://practicaldermatology.com/news/Johnson-johnson-completes-acquisition-yellow-jersey-therapeutics/2467362/Johnson & Johnson has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody being evaluated for the treatment of atopic dermatitis
- AQUA Dermatology Partners With First Coast Mohshttps://practicaldermatology.com/news/aqua-dermatology-partners-first-coast-mohs/2467290/AQUA Dermatology, backed by private-equity firms Gryphon Investors and GTCR, announced it now has 110 locations in the southeastern United States and more than 250 practitioners as a result of a new partnership with Jacksonville, Florida-based First Coast Mohs. First Coast Mohs will conti
- Dermavant Receives Approval of Tapinarof for Psoriasis and Atopic Dermatitis in Japanhttps://practicaldermatology.com/news/dermavant-receives-approval-tapinarof-psoriasis-and-atopic-dermatitis-japan/2467170/Dermavant Sciences announced that Japan Tobacco has received approval in Japan for tapinarof c
- Erenumab Associated with Reduced Rosacea-associated Flushing, Chronic Erythemahttps://practicaldermatology.com/news/erenumab-associated-reduced-rosacea-associated-flushing-chronic-erythema/2467166/Erenumab, an anti–calcitonin gene-related peptide (CGRP)-receptor monoclonal antibody, was shown in new research to be effective at reducing the number of days with rosacea-associated erythema and flushing in treated patients.
- Biofrontera Unveils New Red-Light-Emitting Lamp for PDT on Actinic Keratoseshttps://practicaldermatology.com/news/biofronters-unveils-new-red-light-emitting-lamp-pdt-actinic-keratoses/2467140/Biofrontera Inc. announced the launch of the RhodoLED XL, a new red-light-emitting LED lamp approved by the US Food and Drug Administration (FDA) in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy of actinic keratoses of mild-to-moderate sever
- Vyne Therapeutics Doses First Patient in Phase 2b Vitiligo Trial of Novel BET Inhibitorhttps://practicaldermatology.com/news/vyne-therapeutics-doses-first-patient-phase-2b-vitiligo-trial-novel-bet-inhibitor/2467132/Vyne Therapeutics announced that the first subject has been dosed in a phase 2b trial evaluating VYN201 in subjects with either active or stable nonsegmental vitiligo. VYN201 is a novel pan-bromodomain and extra-terminal domain (BET) inhibitor designed for local administration. Topline data from
- FDA Approves Gel for Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-gel-axillary-hyperhidrosis/2467109/The US Food and Drug Administration (FDA) has approved a new prescription gel used to treat axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 and older, manufacturer Botanix Pharmaceuticals announced. Sofdra (sofpironium) is the first chemical entity approved b